(S)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo(4,3-c)pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one (CAS No: 2212022-56-3) is a key pharmaceutical intermediate used in the synthesis of APIs Orforglipron. This compound serves as an essential raw material in API development and synthesis. Explore detailed chemical properties, molecular data, structure information, and verified global suppliers, manufacturers, and distributors of this API intermediate on apicule.
Alternate Names: 2H-Imidazol-2-one, 1-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-4,5,6,7-tetrahydro-4-methyl-2H-pyrazolo[4,3-c]pyridin-3-yl]-3-(4-fluoro-1-methyl-1H-indazol-5-yl)-1,3-dihydro-, 1-[(4S)-2-(4-Fluoro-3,5-dimethylphenyl)-4,5,6,7-tetrahydro-4-methyl-2H-pyrazolo[4,3-c]pyridin-3-yl]-3-(4-fluoro-1-methyl-1H-indazol-5-yl)-1,3-dihydro-2H-imidazol-2-one
CAS No: 2212022-56-3
PubChem CID: 139328336
Mol Formula: C26H25F2N7O
Mol Weight: 489.5 g/mol
Used in API: Orforglipron
IUPAC Name: 1-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-3-yl]-3-(4-fluoro-1-methylindazol-5-yl)imidazol-2-one
API Intermediate Description: (S)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3-c]pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one is a critical advanced intermediate used in the synthesis of Orforglipron. It forms the core scaffold of the oral, non-peptide GLP-1 receptor agonist designed for Type 2 diabetes and obesity.
